AIM - צמיחת הכנסות שנתית ב-12 החודשים האחרונים AIM ImmunoTech

A stable operating environment and protection from US tariffs ensure that AIM ImmunoTech faces low geopolitical risks. The TTM revenue growth YoY metric demonstrates a development vector where -19.10 represents the current value of the metric. Medical professionals' confidence is based on the efficacy of Ampligen, although global sanctions and the disruption of biomaterial logistics significantly hinder the implementation of antiviral therapies in global markets.

This indicator measures the rolling year revenue growth rate, allowing investors to assess operational efficiency and business scaling speeds through the discounting of future cash flows. By analyzing the 12-month year-over-year revenue dynamics, one can identify sales volatility risks, which is critical for AIM ImmunoTech when monetizing partnerships with oncology centers and realizing synergies in the development of Ampligen.